Beam Therapeutics (BEAM) CEO John M. Evans Sells $600K of Stock

Beam Therapeutics Inc. CEO John M. Evans sold 25,000 shares of the biotechnology company on October 16, 2026. The transaction was revealed in a Form 4 filing submitted to the Securities and Exchange Commission.

Inside John M. Evans's Beam Trade

The stock was sold at an average price of $23.98 per share, bringing the total value of the transaction to $599,595.00. This move followed a pre-arranged trading plan. After the sale, the chief executive directly held 1047205.0 shares, which represented a 2.33% drop in his personal holding.

Other Institutional Activity in Beam Therapeutics

Other large funds adjusted their positions during the middle of 2026. Farallon Capital Management LLC grew its holdings by 101350 shares, ending with 10236396.0 shares worth about $240248207.0. ARK Investment Management, LLC cut its stake by 1898940 shares, holding 10234862.0 shares valued at about $240212204.0. Arch Venture Management, Llc kept its stake steady at 4540132.0 shares worth roughly $106556894.0. Amova Asset Management Americas Inc reduced its position by 370716 shares to finish with 3455043.0 shares valued at about $81089856.0. Sumitomo Mitsui Trust Group, Inc. also cut its holdings by 370716 shares, leaving it with 3455043.0 shares worth roughly $81089856.0.

Beam Therapeutics Inc. Stock Down 5.4%

The shares recently traded around $23.40 as of October 17, 2026.

Recent Earnings

Recent financial reports showed trailing twelve-month revenue of $156035008.0 alongside a trailing twelve-month loss of $0.68 per share.

Dividend

Beam Therapeutics does not pay a dividend.

Insider Buying and Selling at Beam Therapeutics Inc.

Earlier insider trades included Fmr LLC selling 251488.0 shares on June 26, 2026, for about $8867466.88. John M. Evans previously sold 50000.0 shares on June 30, 2026. Amy Simon sold 373.0 shares on June 30, 2026, for $12954.0, followed by another sale of 16667.0 shares on July 27, 2026, for $429037.0.

Analysts Set New Price Targets

Several firms updated their outlooks in recent months. B of A Securities reiterated a buy rating with a $47.0 target on July 8, 2026. HC Wainwright & Co. kept a buy rating and an $80.0 target on August 25, 2026, and reaffirmed it on October 15, 2026. Wedbush maintained an outperform rating with a $65.0 target on September 9, 2026, and again on October 14, 2026.

About Beam Therapeutics

Beam Therapeutics Inc. is a Cambridge, Massachusetts-based biotechnology firm focused on developing precision genetic medicines for patients with serious diseases. The company employs 540 people and utilizes advanced editing techniques to address complex medical conditions.

Bottom Line

Investors will look toward the upcoming financial results scheduled for November 3, 2026, for further updates on the company's clinical progress and financial standing. The insider sale was executed pursuant to a pre-arranged Rule 10b5-1 plan.